The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity

Journal of Neuro-Oncology

Volumn 138, Issue 2, 2018, Pages 299-306

  Rahman, Rifaquat ^a   Cortes, Alfonso ^b   Niemierko, Andrzej ^a   Oh, Kevin S ^a   Flaherty, Keith T ^c   Lawrence, Donald P ^c   Sullivan, Ryan J ^c   Shih, Helen A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Brain metastases; Immunotherapy; Melanoma; Radionecrosis; Stereotactic radiosurgery

Indexed keywords

B RAF KINASE; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MUTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION NECROSIS; RETROSPECTIVE STUDY; SKULL IRRADIATION; STEREOTACTIC RADIOSURGERY; TIME TO TREATMENT; BRAIN TUMOR; DISEASE EXACERBATION; FEMALE; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECONDARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85042106983     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-018-2795-7     Document Type: Article

References (22)

1. Johnson JD, Young B (1996) Demographics of brain metastasis. Neurosurg Clin N Am 7:337–344
2. Sampson JH, Carter JH, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11–20. 10.3171/jns.1998.88.1.0011
3. Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 33:1889–1894. 10.1200/JCO.2014.56.2736
4. Margolin K, Ernstoff MS, Hamid O et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459–465. 10.1016/S1470-2045(12)70090-6
5. Schachter J, Ribas A, Long GV et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet Lond Engl. 10.1016/S0140-6736(17)31601-X
6. Goldberg SB, Gettinger SN, Mahajan A et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:976–983. 10.1016/S1470-2045(16)30053-5
7. Long GV, Atkinson V, Menzies AM et al (2017) A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol 35:9508
8. Tawbi HA-H, Forsyth PA, Algazi AP et al (2017) Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. J Clin Oncol 35:9507
9. Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16:e498-509. 10.1016/S1470-2045(15)00007-8
10. Qian JM, Yu JB, Kluger HM, Chiang VLS (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122:3051–3058. 10.1002/cncr.30138
11. Cohen-Inbar O, Shih H-H, Xu Z et al (2017) The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. J Neurosurg 1–8. 10.3171/2016.9.JNS161585
12. Belcaid Z, Phallen JA, Zeng J et al (2014) Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PloS ONE 9:e101764. 10.1371/journal.pone.0101764
13. Kiess AP, Wolchok JD, Barker CA et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368–375. 10.1016/j.ijrobp.2015.01.004
14. Kato S, Goodman A, Walavalkar V et al (2017) Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res Off J Am Assoc Cancer Res 23:4242–4250. 10.1158/1078-0432.CCR-16-3133
15. Berghoff AS, Preusser M (2017) Targeted therapies for melanoma brain metastases. Curr Treat Options Neurol 19:13. 10.1007/s11940-017-0449-2
16. Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res Off J Am Assoc Cancer Res 15:7412–7420. 10.1158/1078-0432.CCR-09-1624
17. Champiat S, Dercle L, Ammari S et al (2016) Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 10.1158/1078-0432.CCR-16-1741
18. Patel KR, Lawson DH, Kudchadkar RR et al (2015) Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro-Oncol 17:1312–1321. 10.1093/neuonc/nov093
19. Chandra RA, Wilhite TJ, Balboni TA et al (2015) A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 4:e1046028. 10.1080/2162402X.2015.1046028
20. Kohutek ZA, Yamada Y, Chan TA et al (2015) Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol 125:149–156. 10.1007/s11060-015-1881-3
21. Colaco RJ, Martin P, Kluger HM et al (2016) Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 125:17–23. 10.3171/2015.6.JNS142763
22. Fang P, Jiang W, Allen P et al (2017) Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neurooncol 133:595–602. 10.1007/s11060-017-2470-4